Order byBest matchMost fresh
23andMe to Be Bought by Biotech Company for $256 Million
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.
Timeline: 23andMe’s Journey From DNA Testing Pioneer to Bankruptcy Sale
What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.
Biotech company Regeneron buying 23andMe for $256 million
The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.
Stock Movers: 23andMe, Reddit, Royal Caribbean
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Explore more
Feedback